# Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

> **NCT07089186** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Hospital-acquired Bacterial Pneumonia (HABP)
- Ventilator-associated Bacterial Pneumonia (VABP)
- Complicated Intra-abdominal Infection (cIAI)
- Complicated Urinary Tract Infection (cUTI)
- Bloodstream Infection (BSI)

## Interventions

- **DRUG:** Meropenem and Pralurbactam
- **DRUG:** Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)

## Key facts

- **NCT ID:** NCT07089186
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-12
- **Primary completion:** 2026-12
- **Final completion:** 2027-04
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07089186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07089186, "Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07089186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*